Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note published on Tuesday, analysts Jyoti Prakash and Arron Aatkar said the company was on track to reach...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by strong AGAMREE sales across Europe. The company expects to hit cash flow breakeven in Q3 2026 without raising additional capital. AOTI Inc (AIM:AOTI) has published a major study showing its wound oxygen therapy healed 64.8% of patients with chronic wounds that had resisted treatment for an average of seven months. The study, which involved 3,126-patients, also reported hospitalisation rates of just 3.7% and amputation rates of 6.1%. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) is about to start screening patients for its POLB-001 trial across six UK sites, targeting a serious complication of cancer immunotherapy. Interim data is expected this summer, with partnering talks already intensifying ahead of the readout. Solvonis Therapeutics PLC (LSE:SVNS) is pushing its alcohol use disorder drug SVN-001 into phase III rather than doing an early licensing deal. CEO Anthony Tennyson says shareholder value is greater at the end of a successful trial than before it. International Biotechnology Trust (LSE:IBT) says M&A activity in biotech is running hot, with the proposed KalVista deal the latest example. Portfolio manager Ailsa Craig says big pharma's patent cliff problem is keeping activity at exceptional levels. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Santhera Pharmaceuticals Holding AG (SPHDF) reports a significant revenue increase and strategic market expansions, despite facing pricing pressures and reimbursement delays.

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) CFO Catherine Isted joined Proactive's Stephen Gunnion to discuss a standout 2025, with total revenues almost doubling to CHF 77.2 million — well ahead of guidance — driven by strong AGAMREE sales across Europe and partner contributions from the US and China. European approvals now cover around 80% of major markets, with Spain and Italy the next launches. Long-term data continues to support AGAMREE's differentiated safety profile versus traditional corticosteroids, while a new Asia-Pacific licensing deal and further partnership opportunities are being explored. Operating expenses fell to CHF 53 million, and the company expects to reach cash flow breakeven in Q3 2026 — without needing to raise additional capital. For more insights into Santhera Pharmaceuticals’ strategy and growth outlook, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #SantheraPharmaceuticals #AGAMREE #DMD #Biotech #PharmaNews #HealthcareInnovation #DrugDevelopment #RareDisease #Investing #BiotechStocks #EuropeMarkets

EnergyPathways PLC (AIM:EPP) has launched Front End Engineering and Design for what could become the world's largest compressed air energy storage project. Pre-FEED work with Siemens Energy confirmed the project's viability, with a £15 million financing package now in place to fund the next phase. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has secured FDA Fast Track Designation for its lead cancer drug iSCIB1+ in advanced melanoma. Phase II trial data shows 77% progression-free survival at 20 months, compared with 43% for the current standard of care. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) is advancing partnering talks as interim data from its TOPICAL trial approaches this summer. The company estimates the addressable market for POLB 001 at more than $10 billion, with partner interest increasing as data nears. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) reported revenues up 97% to CHF 77.2 million, well ahead of guidance, driven by strong sales of its Duchenne muscular dystrophy drug AGAMREE. The company expects to reach cash flow breakeven in Q3 2026 without further fundraising. Powerhouse Energy Group PLC (AIM:PHE, FRA:BT81) has won a £260,000 contract with a Welsh battery developer, its first revenue outside its Engsolve engineering arm. The company currently has around ten live enquiries it believes could become revenue-generating projects. Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) says its 8MVA site in the United Arab Emirates will become the first pilot deployment under its proposed Bitdeer collaboration. The site could generate around $300,000 per MVA in annual infrastructure revenue alongside 8.3 Bitcoin per MVA per year. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss specialty pharma group listed on the SIX Swiss Exchange, has reconfirmed it expects to reach cash...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending that its Duchenne muscular dystrophy (DMD) treatment AGAMREE be...

November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the release of top-line results from the company’s GUARDIAN study, data that promises to reshape the...

Under the agreement, Santhera will receive an initial payment of $40m from Nxera.

Sales of the drug to the Indian market will commence in the fourth quarter of 2025.